TP 3654: aminobutyric acid as a spacer and extended the molecule to include Gly-Gly-Ala-Gly this analog is referred to as TP3654; amino acid sequence in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 66598080 |
| CHEMBL ID | 3975308 |
| SCHEMBL ID | 102560 |
| SCHEMBL ID | 19986953 |
| SCHEMBL ID | 20794171 |
| SCHEMBL ID | 22421478 |
| MeSH ID | M0301521 |
| Synonym |
|---|
| SCHEMBL102560 |
| CHEMBL3975308 |
| sgi-9481 |
| SCHEMBL19986953 |
| tp3654 |
| 1361951-15-6 |
| tp-3654 |
| HY-101126 |
| CS-6293 |
| us9416132, 8-31 |
| bdbm242374 |
| 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol |
| AKOS032960444 |
| BS-15262 |
| 2-[4-[[3-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexyl]propan-2-ol |
| BCP30070 |
| tp3654; tp 3654 |
| SB17245 |
| unii-eob0n7boy4 |
| EOB0N7BOY4 , |
| 4-((3-(3-(trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino) -trans-cyclohexyl)propan-2-ol |
| 2-(4-((3-(3-(trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino)cyclohexyl)propan-2-ol |
| SCHEMBL20794171 |
| nsc-805149 |
| nsc805149 |
| EX-A1828 |
| tp 3654 |
| C72454 |
| 2-(trans-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol |
| xrnvabdyqlhoda-skhkeopysa-n |
| NCGC00511354-02 |
| S6774 |
| SCHEMBL22421478 |
| AC-36196 |
| A857573 |
| xrnvabdyqlhoda-jcnlheqbsa-n |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 8.2891 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| Interferon beta | Homo sapiens (human) | Potency | 8.2891 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | Ki | 0.0050 | 0.0000 | 0.0084 | 0.0160 | AID1551194 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular space | Interferon beta | Homo sapiens (human) |
| extracellular region | Interferon beta | Homo sapiens (human) |
| nucleus | Serine/threonine-protein kinase pim-1 | Homo sapiens (human) |
| nucleoplasm | Serine/threonine-protein kinase pim-1 | Homo sapiens (human) |
| nucleolus | Serine/threonine-protein kinase pim-1 | Homo sapiens (human) |
| cytoplasm | Serine/threonine-protein kinase pim-1 | Homo sapiens (human) |
| cytosol | Serine/threonine-protein kinase pim-1 | Homo sapiens (human) |
| plasma membrane | Serine/threonine-protein kinase pim-1 | Homo sapiens (human) |
| cytoplasm | Serine/threonine-protein kinase pim-1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1551196 | Selectivity ratio of IC50 for PI3kdelta (unknown origin) to Ki for PIM1 (unknown origin) | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | PIM kinase inhibitors: Structural and pharmacological perspectives. |
| AID1551197 | Selectivity ratio of IC50 for PI3kalpha (unknown origin) to Ki for PIM1 (unknown origin) | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | PIM kinase inhibitors: Structural and pharmacological perspectives. |
| AID1551194 | Inhibition of PIM1 (unknown origin) up to 120 mins by Michaelis-Menten plot analysis | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | PIM kinase inhibitors: Structural and pharmacological perspectives. |
| AID1551195 | Selectivity ratio of IC50 for PI3kgamma (unknown origin) to Ki for PIM1 (unknown origin) | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | PIM kinase inhibitors: Structural and pharmacological perspectives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||